GSK Collaborates With Angiochem to Develop LSDs Medication

GSK Collaborates With Angiochem to Develop LSDs Medication

As per recent reports, it has been revealed that GSK has entered into a deal with Angiochem in which both the organizations will be working together to develop treatments for Lysosomal Storage Diseases (LSDs). Company officials are of the view that both the organizations are master in their fields, which will help them discover treatment for the disease.

If the pair will be able to develop the medicine then they will be get more than $300 million. Industry experts said that Angiochem will use its rich knowledge of creating novel therapeutic treatments, while GSK will apply its commercialization capability to create medicines for the rare disease.

Drugs are available to treat the problem, but they are not able to restore enzyme function in the Central Nervous System (CNS), which is necessary to derive best results of the medicine. The main aim of Angiochem will be to prepare a drug, which penetrates in the CNS and brings a decline in the symptoms of LSDs.

Lysosomal storage diseases is quite a rare disease, which affects one in 1, 00,000 people. It generally affects children who mostly die at young age or after a few months of the detection of the disease. LSD is not a single disease, but a group of diseases such as Tay Sachs Disease, Fabry Disease, Gaucher's Disease, Pompe Disease and Hunter syndrome.

"”Our collaboration with GSK reflects our belief in the need to effectively address neurological symptoms of lysosomal storage diseases. We are pleased to collaborate with GSK, a committed leader in this rare disease area”, said Jean-Paul Castaigne, who is the President and CEO of Angiochem. Jean further affirmed that the development of the drug will increase their resources as well in the field of EPiC-enzymes.


FrenchTribune Specials

While you may share your love for coffee with large number of people across the world, there is a possibility that consumption level may differ greatly. Why some people could only consume less amount of coffee, while others can take several cups a day is now defined by presence of a gene variant in an individual’s body.

The study that...

Exxon reports 46% decline in First Quarter earning

On Thursday, Exxon reported a 46% decline in earnings in the first quarter, by earning $4.9 billion compared with $9.1 billion in the same quarter a year ago. Exxon's top and bottom lines declined due to lower oil prices.

It was the...

Most Popular

MIT team publishes slow-motion video of sneeze

Lydia Bourouiba, mathematical physicist and head of a...

Report: Google, Facebook, and Twitter are ‘the lifeblood of Daesh’

According to a new report released by the UK Home...

Milk protein helps make edible packaging for food products

Most of the food products come wrapped in plastic...

Poll

Can Greece Come out of Economic Problems: